Cephalon, Inc.(CEPH)- NASDAQ
CEPH is defunct.
  • Oct. 11, 2011, 6:21 PM

    TE Connectivity (TEL) will replace Cephalon (CEPH) in the S&P 500 index after the close of trading on Friday, October 14. Cephalon is being acquired by Teva Pharmaceutical Industries (TEVA) in a deal expected to be completed on or about that date pending final approvals. TEL +6.9% AH.

    | Oct. 11, 2011, 6:21 PM
  • Oct. 10, 2011, 11:27 AM

    Teva Pharmaceutical (TEVA +2.2%) moves higher this morning after the FTC approved its merger with Cephalon (CEPH +0.4%) over the weekend. As part of the approval, Teva is required to divest two abbreviated new drug applications for fentanyl citrate lozenges, a generic version of Actiq, and cyclobenzaprine ER capsules, the generic version of Amrix.

    | Oct. 10, 2011, 11:27 AM
  • Oct. 7, 2011, 5:30 PM

    Teva Pharmaceuticals (TEVA) rises 0.7% AH after the FTC approves Teva's acquisition of Cephalon (CEPH). In return for the go-ahead, Teva has agreed to divest two drug applications, and grant non-exclusive rights to an undisclosed company to market the generic version of Cephalon's Provigil drug. European approval is still pending. (previously)

    | Oct. 7, 2011, 5:30 PM
  • Aug. 2, 2011, 4:19 PM
    Cephalon (CEPH): Q2 EPS of $1.62 misses by $0.44. Revenue of $730M (+1.6% Y/Y) misses by $34M. (PR)
    | Aug. 2, 2011, 4:19 PM
  • Aug. 2, 2011, 12:10 AM

    Notable earnings after Tuesday's close: ACAS, CAVM, CBL, CBS, CEPH, DEI, HK, HRS, HTZ, IO, LBTYA, LNC, MDRX, NLC, OPEN, RKT, SFSF, SGY, TIE, UNM, VCLK, VMC, WBMD, XCO, XL

    | Aug. 2, 2011, 12:10 AM
  • Jul. 26, 2011, 4:54 PM

    Valeant Pharmaceuticals (VRX) has made a takeover approach for Swedish specialty drug maker Meda, WSJ reports; if concluded, a deal could be worth more than $4B. The last big deal Valeant attempted, a hostile takeover offer for Cephalon (CEPH), ultimately failed.

    | Jul. 26, 2011, 4:54 PM
  • Jul. 14, 2011, 11:33 AM

    Cephalon (CEPH +0.2%) shareholders approve a $6.8B takeover offer from Teva Pharmaceuticals (TEVA -0.4%) at $81.5/share. (PR)

    | Jul. 14, 2011, 11:33 AM
  • Jun. 14, 2011, 6:29 AM

    The FTC asks for more info on Teva's (TEVA -2.3%) planned $6.8B acquisition of Cephalon (CEPH). The firms say they're cooperating with the request, and will extend the deadline for antitrust clearance until 30 days after they've complied. Both Teva and Cephalon still expect the deal to move forward in Q3.

    | Jun. 14, 2011, 6:29 AM
  • May 4, 2011, 8:23 AM
    Valeant (VRX) failed in its attempt to snag Cephalon (CEPH), but the company is hardly nursing its wounds. CEO Michael Pearson says Valeant is already in talks with other potential takeover targets and has the resources to pursue even larger deals than Cephalon would have been.
    | May 4, 2011, 8:23 AM
  • May 3, 2011, 4:23 PM
    Cephalon (CEPH): Q1 EPS of $2.09 beats by $0.05. Revenue of $736M (+28% Y/Y) misses by $15M. (PR)
    | May 3, 2011, 4:23 PM
  • May 3, 2011, 12:10 AM
    Notable earnings after Tuesday's close: ACAS, AMMD, AUY, BEXP, CAR, CBS, CENX, CEPH, CMCSA, CRL, DEI, DGI, EXEL, FSLR, GMCR, GNK, GNW, GXP, HRS, JAZZ, JKHY, KGC, LVS, MCK, MOLX, MOTR, NYGN, OPEN, PEET, PLT, PXD, QSFT, SONS, TE, THOR, THQI, UNM, VCLK, VRTX, XCO, XL
    | May 3, 2011, 12:10 AM | 4 Comments
  • May 2, 2011, 9:00 AM

    Premarket gainers: ICO +31%. TIVO +15%. TGE +12%. ZSL +11%. STEM +8%. LOCM +8%. SPPI +8%. CTIC +7%. DRL +7%. CEPH +5%. HRBN +5%. TLCR +5%. MOVE +4%. PCX +4%. TEVA +4%. AEZS +3%. MPEL +3%. NFLX +3%. CPST +4%.
    Losers: AGQ -12%. VRX -9%. GPL -7%. THC -6%. EXK -6%. SLV -6%. SIVR -6%. AG -5%. SLW -5%. GRS -4%. SVM -3%. SIFY -4%. HL -3%. ACI -3%. PAAS -3%.

    | May 2, 2011, 9:00 AM
  • May 2, 2011, 7:25 AM
    Valeant (VRX) -5% after Teva (TEVA +0.9%) snags Cephalon (CEPH +4%) for $6.8B. Valeant had been pursuing Cephalon as part of its bet that the drug industry’s traditional growth model - heavy R&D spending - is broken and needs to be replaced by acquisitions.
    | May 2, 2011, 7:25 AM
  • May 2, 2011, 7:09 AM

    Teva (TEVA +0.9%) to buy Cephalon (CEPH) for $6.8B, or $81.50/share. It's a 6% premium to CEPH's Friday close, and a blow to Valeant (VRX) which had been pursuing Cephalon. (PR)

    | May 2, 2011, 7:09 AM
  • Apr. 6, 2011, 8:34 AM

    Cephalon's (CEPH) board rejects a $5.7B bid from Canada's Valeant (VRX) for being too low. One analyst, though, expects the purchase to occur. “There will be a dance and courtship and there will be a deal at the end of that process,” he says. (previous)

    | Apr. 6, 2011, 8:34 AM
  • Apr. 1, 2011, 3:37 PM
    Michael Pearson is leading the bid by Valeant Pharmaceuticals (VRX) to take over Cephalon (CEPH), his biggest bet so far on a theory that the drug industry’s traditional growth model - heavy R&D spending - is broken. The surest road to growth, he says, is through acquisitions.
    | Apr. 1, 2011, 3:37 PM
Company Description
Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system ("CNS"), pain, oncology and inflammatory disease. In addition to conducting an active... More
Sector: Healthcare
Industry: Biotechnology
Country: United States